Predictive value of peripheral blood lymphocyte count in breast cancer patients treated with primary chemotherapy

Breast

Volumn 21, Issue 4, 2012, Pages 468-474

  Vicente Conesa, Maria Angeles ^a   Garcia Martinez, Elena ^a   Gonzalez Billalabeitia, Enrique ^a   Chaves Benito, Asuncion ^a   Garcia Garcia, Teresa ^a   Vicente Garcia, Vicente ^a   Ayala de la Peña, Francisco ^a  

^a HOSPITAL MORALES MESEGUER   (Spain)

Author keywords

Anti cancer immunity; Breast cancer; Lymphocyte; Lymphopenia; Neoadjuvant chemotherapy; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE; PROGESTERONE RECEPTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEBRILE NEUTROPENIA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG METASTASIS; LYMPH NODE DISSECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PREDICTIVE VALUE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR IMMUNITY; VOMITING;

EID: 84863875631     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2011.11.002     Document Type: Article

References (44)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Chen A.M., Meric-Bernstam F., Hunt K.K., Thames H.D., Oswald M.J., Outlaw E.D., et al. Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol 2004, 22:2303-2312.
3. Beriwal S., Schwartz G.F., Komarnicky L., Garcia-Young J.A. Breast-conserving therapy after neoadjuvant chemotherapy: long-term results. Breast J 2006, 12:159-164.
4. Chia S., Swain S.M., Byrd D.R., Mankoff D.A. Locally advanced and inflammatory breast cancer. J Clin Oncol 2008, 26:786-790.
5. Kaufmann M., von Minckwitz G., Bear H.D., Buzdar A., McGale P., Bonnefoi H., et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 2007, 18:1927-1934.
6. Mahmoud S.M.A., Paish E.C., Powe D.G., Macmillan R.D., Grainge M.J., Lee A.H., et al. Tumor-Infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011, 29:1949-1955.
7. Bear H.D., Anderson S., Smith R.E., Gever C.E., Mamounas E.P., Fisher B., et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol 2006, 24:2019-2027.
8. Rastogi P., Anderson S.J., Bear H.D., Geyer C.E., Kahlenberg M.S., Robidoux A., et al. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol 2008, 26:778-785.
9. Swann J.B., Smyth M.J. Immune surveillance of tumors. J Clin Invest 2007, 117:1137-1146.
10. Liyanage U.K., Moore T.T., Joo H.G., Tanaka Y., Herrmann V., Doherty G., et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002, 169:2756-2761.
11. de Visser K.E., Eichten A., Coussens L.M. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006, 6:24-37.
12. Rech A.J., Mick R., Kaplan D.E., Chang K.M., Domchek S.M., Vonderheide R.H. Homeostasis of peripheral FoxP3(+) CD4 (+) regulatory T cells in patients with early and late stage breast cancer. Cancer Immunol.Immunother 2010, 59:599-607.
13. Demaria S., Volm M.D., Shapiro R.L., Yee H.T., Oratz R., Formenti S.C., et al. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin Cancer Res 2001, 7:3025-3030.
14. Formenti S.C., Demaria S. Effects of chemoradiation on tumor-host interactions: the immunologic side. J Clin Oncol 2008, 26:1562-1563.
15. Mackall C.L., Fleisher T.A., Brown M.R., Magrath I.T., Shad A.T., Horowitz M.E., et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 1994, 84:2221-2228.
16. Ray-Coquard I., Ghesquiere H., Bachelot T., Borg C., Biron P., Sebban C., et al. Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas. Br J Cancer 2001, 85:816-822.
17. Ray-Coquard I., Borg C., Bachelot T., Sebban C., Philip I., Clapisson G., et al. Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy. Br J Cancer 2003, 88:181-186.
18. Papatestas A.E., Lesnick G.J., Genkins G., Aufses A.H. The prognostic significance of peripheral lymphocyte counts in patients with breast carcinoma. Cancer 1976, 37:164-168.
19. Pattison C.W., Woods K.L., Morrison J.M. Lymphocytopenia as an independent predictor of early recurrence in breast cancer. Br J Cancer 1987, 55:75-76.
20. Qiu H., Xiao-Jun W., Zhi-Wei Z., Gong C., Guo-Quiang W., Li-Yi Z., et al. The prognostic significance of peripheral T-lymphocyte subsets and natural killer cells in patients with colorectal cancer. Hepatogastroenterology 2009, 56:1310-1315.
21. Soygur T., Beduk Y., Baltaci S., Yaman O., Tokgoz G. The prognostic value of peripheral blood lymphocyte subsets in patients with bladder carcinoma treated using neoadjuvant M-VEC chemotherapy. BJU Int 1999, 84:1069-1072.
22. Ray-Coquard I., Cropet C., Van G.M., Sebban C., Le Cesne A., Judson I., et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res 2009, 69:5383-5391.
23. Tolaney S.M., Najita J., Winer E.P., Burstein H.J. Lymphopenia associated with adjuvant anthracycline/ taxane regimens. Clin Breast Cancer 2008, 8:352-356.
24. Mellios T., Ko H.L., Beuth J. Impact of adjuvant chemo- and radiotherapy on the cellular immune system of breast cancer patients. In Vivo 2010, 24:227-230.
25. Kotsakis A., Sarra E., Peraki M., Koukourakis M., Apostolaki S., Souglakos J., et al. Docetaxel-induced lymphopenia in patients with solid tumors: a prospective phenotypic analysis. Cancer 2000, 89:1380-1386.
26. Tong A.W., Seamour B., Lawson J.M., Ordonez G., Vukelia S., Hyman W., et al. Cellular immune profile of patients with advanced cancer before and after taxane treatment. Am J Clin Oncol 2000, 23:463-472.
27. Zhang H., Chua K.S., Guimond M., Kapoor V., Brown M.V., Fleisher T.A., et al. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat Med 2005, 11:1238-1243.
28. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002, 3:991-998.
29. Sakaguchi S., Yamaguchi T., Nomura T., Ono M. Regulatory T cells and immune tolerance. Cell 2008, 133:775-787.
30. Menard C., Martin F., Apetoh L., Bouyer F., Ghiringhelli F. Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. Cancer Immunol Immunother 2008, 57:1579-1587.
31. Murta E.F., de Andrade J.M., Falcao R.P., Bighetti S. Lymphocyte subpopulations in patients with advanced breast cancer submitted to neoadjuvant chemotherapy. Tumori 2000, 86:403-407.
32. Guillaume T., Rubinstein D.B., Symann M. Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. Blood 1998, 92:1471-1490.
33. Lake R.A., Robinson B.W. Immunotherapy and chemotherapy-a practical partnership. Nat Rev Cancer 2005, 5:397-405.
34. Dummer W., Niethammer A.G., Baccala R., Lawson B.R., Wagner N., Reisfeld R.A., et al. T cell homeostatic proliferation elicits effective antitumor autoimmunity. J Clin Invest 2002, 110:185-192.
35. Ladoire S., Mignot G., Dabakuyo S., Arnould L., Apetoh L., Rebé C., et al. In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival. J Pathol 2011, [Epub ahead of print]. 10.1002/path. 2866.
36. Lissoni P., Brivio F., Fumagalli L., Messina G., Ghezzi V., Frontini L., et al. Efficacy of cancer chemotherapy in relation to the pretreatment number of lymphocytes in patients with metastatic solid tumors. Int J Biol Markers 2004, 19:135-140.
37. Oki Y., Yamamoto K., Kato H., Kuwatsuka Y., Taii H., Kagami Y., et al. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab. Eur J Haematol 2008, 81:448-453.
38. Claude L., Perol D., Ray-Coquard I., Petit T., Blay J.Y., Carrie C., et al. Lymphopenia: a new independent prognostic factor for survival in patients treated with whole brain radiotherapy for brain metastases from breast carcinoma. Radiother Oncol 2005, 76:334-339.
39. Castillo J.J., Morales D., Quinones P., Cotrina E., Desposorio C., Beltran B. Lymphopenia as a prognostic factor in patients with peripheral T-cell lymphoma, unspecified. Leuk Lymphoma 2010, 51:1822-1828.
40. Ascierto M.L., Kmieciak M., Idowu M.O., Manjili R., Zhao Y., Grimes M., et al. A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Res Treat 2011, 10.1007/s10549-011-1470-x.
41. Rody A., Holtrich U., Pusztai L., Liedtke C., Gaetje R., Ruckhaeberle E., et al. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res 2009, 11:R15.
42. Nieto Y., Shpall E.J., McNiece I.K., Nawaz S., Beaudet J., Rosinki S., et al. Prognostic analysis of early lymphocyte recovery in patients with advanced breast cancer receiving high-dose chemotherapy with an autologous hematopoietic progenitor cell transplant. Clin Cancer Res 2004, 10:5076-5086.
43. Porrata L.F., Ingle J.N., Litzow M.R., Geyer S., Markovic S.N. Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. Bone Marrow Transplant 2001, 28:865-871.
44. De Angulo G., Hernandez M., Morales-Arias J., Herzog C.E., Anderson P., Wolff J., et al. Early lymphocyte recovery as a prognostic indicator for high-risk Ewing sarcoma. J Pediatr.Hematol Oncol 2007, 29:48-52.